Guardant Health beat expectations with a Q1 2026 revenue surge, raised full-year guidance, and pointed to continued momentum in oncology and screening. The company reported Q1 revenue of $301.7 million, up 48% year over year, and increased its 2026 revenue outlook to $1.30 billion–$1.32 billion. Guardant said growth was driven by minimal residual disease testing volume and reimbursement, including Reveal volumes more than doubling year over year. The firm also highlighted an upgrade to Guardant360 Tissue to include whole-transcriptome RNA testing, describing the change as a potential volume catalyst. Beyond financials, the company said it has submitted data packages to CMS’s MolDx program across breast cancer surveillance, immunotherapy monitoring, and chemotherapy monitoring. For the biotech industry, these CMS-linked steps can materially affect adoption and reimbursement pathways for liquid biopsy platforms.